Composite lymphoma

Composite lymphoma is a rare hematologic malignancy defined by the simultaneous occurrence of two or more distinct types of lymphoma within the same patient, typically presenting in the same anatomical site (such as a single lymph node) or in different sites at the same time. Most commonly, composite lymphoma involves the coexistence of a Hodgkin lymphoma component alongside a non-Hodgkin lymphoma component, though combinations of two different non-Hodgkin lymphomas can also occur. The condition primarily affects the lymphatic system, including lymph nodes, spleen, and other lymphoid tissues, and may also involve extranodal sites such as the bone marrow, liver, or gastrointestinal tract. Patients typically present with painless lymphadenopathy (enlarged lymph nodes), and may experience constitutional symptoms such as unexplained fever, night sweats, unintentional weight loss, and fatigue — collectively known as B symptoms. The clinical course and prognosis depend on the specific histological subtypes involved, with the more aggressive component generally dictating the overall behavior of the disease. Diagnosis requires careful histopathological examination, often with immunohistochemistry and molecular studies, to confirm the presence of two distinct lymphoma populations rather than a single transformed lymphoma. Treatment of composite lymphoma is challenging because there is no standardized therapeutic protocol. Management is generally tailored to address the more aggressive lymphoma subtype, and may include combination chemotherapy regimens (such as ABVD for Hodgkin lymphoma components or R-CHOP for diffuse large B-cell lymphoma components), radiation therapy, immunotherapy, or stem cell transplantation in selected cases. Due to its rarity, evidence guiding treatment is largely derived from case reports and small case series, and multidisciplinary discussion is essential for optimal management. Prognosis varies widely depending on the specific lymphoma subtypes, stage at diagnosis, and response to therapy.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Composite lymphoma